Table 4.
Diagnostic efficacy of LMR, AGR, and CEA used alone or in combination to differentiate colon cancer from benign colon diseases.
| Cut off | Sensitivity (%) | Specificity (%) | PLR | NLR | PPV (%) | NPV (%) | AUC (95% CI) | P | |
|---|---|---|---|---|---|---|---|---|---|
| LMR a | 3.78 | 55.38 | 88.77 | 4.93 | .50 | 86.9 | 59.7 | .778(.736−.816) | <.001 |
| AGR a | 1.59 | 66.53 | 71.12 | 2.30 | .47 | 75.6 | 61.3 | .756(.713−.796) | <.001 |
| MPV a | 8.93 | 83.27 | 96.79 | 25.95 | .17 | 97.2 | 81.2 | .894(.862−.922) | <.001 |
| CEA a | 1.35 | 80.08 | 78.07 | 3.65 | .26 | 83.1 | 74.5 | .870(.835−.900) | <.001 |
| LMR a +AGR a | .64 | 65.74 | 88.24 | 5.59 | .39 | 88.2 | 65.7 | .819(.780 − .854) | <.001 |
| LMR a +MPV a | .60 | 82.47 | 94.65 | 15.42 | .19 | 95.4 | 80.1 | .916(.886−.940) | <.001 |
| AGR a +MPV a | .65 | 78.49 | 96.26 | 20.97 | .22 | 96.6 | 76.9 | .923(.894−.946) | <.001 |
| LMR a +CEA a | .47 | 86.45 | 81.82 | 4.75 | .17 | 86.5 | 81.8 | .895(.863−.922) | <.001 |
| AGR a +CEA a | .46 | 84.86 | 80.75 | 4.41 | .19 | 85.5 | 79.9 | .889(.856−.917) | <.001 |
| MPV a +CEA a | .45 | 91.24 | 90.37 | 9.48 | .097 | 92.7 | 88.5 | .950(.925−.968) | <.001 |
| LMR b | 4.58 | 77.29 | 53.22 | 1.65 | .43 | 70.8 | 61.5 | .688(.642−.732) | <.001 |
| AGR b | 1.71 | 83.27 | 42.11 | 1.44 | .40 | 67.9 | 63.2 | .655(.607−.700) | <.001 |
| MPV b | 7.80 | 38.25 | 74.85 | 1.52 | .82 | 69.1 | 45.2 | .571(.523−.619) | .011 |
| CEA b | 3.44 | 43.43 | 87.72 | 3.54 | .64 | 83.8 | 51.4 | .686(.639−.730) | <.001 |
| LMR b +AGR b | .66 | 53.39 | 78.95 | 2.54 | .59 | 78.8 | 53.6 | .717(.671−.759) | <.001 |
| LMR b +MPV b | .65 | 51.39 | 80.70 | 2.66 | .60 | 79.6 | 53.1 | .698(.652−.742) | <.001 |
| AGR b +MPV b | .61 | 62.15 | 69.01 | 2.01 | .55 | 74.6 | 55.4 | .680(.633−.724) | <.001 |
| LMRb+CEA b | .54 | 75.30 | 63.74 | 2.08 | .39 | 75.3 | 63.7 | .746(.702−.787) | <.001 |
| AGR b +CEAb | .58 | 58.57 | 76.02 | 2.44 | .55 | 78.2 | 55.6 | .737(.693−.779) | <.001 |
| MPV b +CEA b | .59 | 51.39 | 83.63 | 3.14 | .58 | 82.2 | 54.0 | .715(.669−.758) | <.001 |
| LMR c | 5.02 | 63.16 | 53.48 | 1.36 | .69 | 55.4 | 61.3 | .595(.542−.646) | .002 |
| AGR c | 1.46 | 30.41 | 89.84 | 2.99 | .77 | 73.2 | 58.5 | .567(.514−.619) | .032 |
| MPV c | 8.98 | 77.78 | 96.79 | 24.24 | .23 | 95.7 | 82.6 | .856(.815−.891) | <.001 |
| CEA c | 1.05 | 77.19 | 66.31 | 2.29 | .34 | 67.7 | 76.1 | .776(.729−.818) | <.001 |
| LMR c +AGR c | .54 | 40.35 | 83.42 | 2.43 | .72 | 69.0 | 60.5 | .610(.558−.661) | .000 |
| LMR c +MPV c | .55 | 74.85 | 95.19 | 15.55 | .26 | 93.4 | 80.5 | .864(.824 − .898) | <.001 |
| AGR c +MPV c | .55 | 71.35 | 96.79 | 22.24 | .30 | 95.3 | 78.7 | .851(.810–.887) | <.001 |
| LMR c +CEA c | .42 | 73.68 | 74.33 | 2.87 | .35 | 72.4 | 75.5 | .779(.733−.821) | <.001 |
| AGR c +CEA c | .43 | 70.18 | 72.19 | 2.52 | .41 | 69.8 | 72.6 | .773(.726−.816) | <.001 |
| MPV c +CEA c | .38 | 84.80 | 84.49 | 5.47 | .18 | 83.3 | 85.9 | .886(.848−.917) | <.001 |
Note. CEA, carcinoembryonic antigen; LMR, lymphocyte-to-monocyte ratio; AGR, albumin-to-globulin ratio; MPV, mean platelet volume; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; AUC, area under curve.
acolon cancer vs healthy controls.
bcolon cancer vs benign colon diseases.
cbenign colon diseases vs healthy controls.